Product Description
AQST-109 is a polymer matrix-based epinephrine prodrug administered as a sublingual film that is applied under the tongue for the rapid delivery of epinephrine. (Sourced from: https://aquestive.com/aquestive-therapeutics-reports-positive-topline-data-from-part-2-of-epiphast-trial-evaluating-aqst-109-epinephrine-oral-film/)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: Fast Track - Anaphylaxis *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Aquestive Therapeutics
Company Location: WARREN NJ 07059
Company CEO: Daniel Barber
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Anaphylaxis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|